Ultragenyx Pharma (RARE) Misses Q4 EPS by 2c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($2.16), $0.02 worse than the analyst estimate of ($2.14). Revenue for the quarter came in at $103.35 million versus the consensus estimate of $101.94 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• UBS Downgrades Core Natural Resources (CNR) to Neutral
• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c